Search

Your search keyword '"Nicholson, Maribeth R."' showing total 179 results
Start Over Author "Nicholson, Maribeth R."
179 results on '"Nicholson, Maribeth R."'

4. Enterococci enhance Clostridioides difficile pathogenesis

Author

Smith, Alexander B., Jenior, Matthew L., Keenan, Orlaith, Hart, Jessica L., Specker, Jonathan, Abbas, Arwa, Rangel, Paula C., Di, Chao, Green, Jamal, Bustin, Katelyn A., Gaddy, Jennifer A., Nicholson, Maribeth R., Laut, Clare, Kelly, Brendan J., Matthews, Megan L., Evans, Daniel R., Van Tyne, Daria, Furth, Emma E., Papin, Jason A., Bushman, Frederic D., Erlichman, Jessi, Baldassano, Robert N., Silverman, Michael A., Dunny, Gary M., Prentice, Boone M., Skaar, Eric P., and Zackular, Joseph P.

Published
2022
Full Text
View/download PDF

5. Intestinal Tuft Cells Are Enriched With Protocadherins.

Author

Stubler, Rachel, Dooley, Sarah A., Edens, Rachel, Nicholson, Maribeth R., and Engevik, Amy C.

Subjects
SMALL intestine, USHER'S syndrome, GENE expression, RNA sequencing, MICROVILLI
Abstract

Intestinal tuft cells are rare cells that regulate diverse functions. They harbor chemosensory receptors and signal to the mucosal immune system in response to external stimuli, though their full function and structure remain unclear. Named for their apical "tuft" of long actin-rich microvilli, tuft cells facilitate chemoreception and other physiological responses. In enterocytes, microvilli are stabilized by intermicrovillar adhesion complexes (IMACs) composed of several proteins, including cadherin-related family member-2 (CDHR2) and cadherin-related family member-5 (CDHR5), Myosin 7b, and Usher syndrome type 1 C (USH1C). We hypothesized that IMACs would be enriched in tuft cells to regulate microvillar organization. Immunostaining of murine intestinal tissue revealed that CDHR2 and CDHR5 colocalize with the tuft cell markers, DCLK1, phospho-EGFR, advillin, and cytokeratin 18. CDHR2 was dispersed throughout murine tuft cells, while CDHR5 was concentrated on the apical surface. USH1C and Myosin 7b were present in tuft cells, but at lower levels. Human single-cell RNA sequencing revealed robust CDHR2 and CDHR5 expression in tuft cells in the small intestine and colon. Immunostaining of human intestinal tissue confirmed CDHR2 and CDHR5 localization to the apical surface of tuft cells. Our findings demonstrate that protocadherins are key components of murine and human intestinal tuft cells. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. A multicenter study to define the epidemiology and outcomes of Clostridioides difficile infection in pediatric hematopoietic cell and solid organ transplant recipients

Author

Mayer, Erick F., Maron, Gabriela, Dallas, Ronald H., Ferrolino, Jose, Tang, Li, Sun, Yilun, Danziger-Isakov, Lara, Paulsen, Grant C., Fisher, Brian T., Vora, Surabhi B., Englund, Janet, Steinbach, William J., Michaels, Marian, Green, Michael, Yeganeh, Nava, Gibson, Joy E., Dominguez, Samuel R., Nicholson, Maribeth R., Dulek, Daniel E., Ardura, Monica I., Rajan, Sujatha, Gonzalez, Blanca E., Beneri, Christy, and Herold, Betsy C.

Published
2020
Full Text
View/download PDF

9. Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children

Author

Nicholson, Maribeth R., Mitchell, Paul D., Alexander, Erin, Ballal, Sonia, Bartlett, Mark, Becker, Penny, Davidovics, Zev, Docktor, Michael, Dole, Michael, Felix, Grace, Gisser, Jonathan, Hourigan, Suchitra K., Jensen, M. Kyle, Kaplan, Jess L., Kelsen, Judith, Kennedy, Melissa, Khanna, Sahil, Knackstedt, Elizabeth, Leier, McKenzie, Lewis, Jeffery, Lodarek, Ashley, Michail, Sonia, Oliva-Hemker, Maria, Patton, Tiffany, Queliza, Karen, Russell, George H., Singh, Namita, Solomon, Aliza, Suskind, David L., Werlin, Steven, Kellermayer, Richard, and Kahn, Stacy A.

Published
2020
Full Text
View/download PDF

10. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor

Author

Reasoner, Seth A., primary, Bernard, Rachel, additional, Waalkes, Adam, additional, Penewit, Kelsi, additional, Lewis, Janessa, additional, Sokolow, Andrew G., additional, Brown, Rebekah F., additional, Edwards, Kathryn M., additional, Salipante, Stephen J., additional, Hadjifrangiskou, Maria, additional, and Nicholson, Maribeth R., additional

Published
2024
Full Text
View/download PDF

15. Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor

Author

Reasoner, Seth A., primary, Bernard, Rachel, additional, Waalkes, Adam, additional, Penewit, Kelsi, additional, Lewis, Janessa, additional, Sokolow, Andrew G., additional, Brown, Rebekah F., additional, Edwards, Kathryn M., additional, Salipante, Stephen, additional, Hadjifrangiskou, Maria, additional, and Nicholson, Maribeth R., additional

Published
2023
Full Text
View/download PDF

22. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition

Author

Davidovics, Zev H., Michail, Sonia, Nicholson, Maribeth R., Kociolek, Larry K., Pai, Nikhil, Hansen, Richard, Schwerd, Tobias, Maspons, Aldo, Shamir, Raanan, Szajewska, Hania, Thapar, Nikhil, de Meij, Tim, Mosca, Alexis, Vandenplas, Yvan, Kahn, Stacy A., and Kellermayer, Richard

Published
2018
Full Text
View/download PDF

23. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition

Author

Davidovics, Zev H., Michail, Sonia, Nicholson, Maribeth R., Kociolek, Larry K., Pai, Nikhil, Hansen, Richard, Schwerd, Tobias, Maspons, Aldo, Shamir, Raanan, Szajewska, Hania, Thapar, Nikhil, de Meij, Tim, Mosca, Alexis, Vandenplas, Yvan, Kahn, Stacy A., and Kellermayer, Richard

Published
2019
Full Text
View/download PDF

24. Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Pediatric Patients

Author

Conover, Katie R., primary, Absah, Imad, additional, Ballal, Sonia, additional, Brumbaugh, David, additional, Cho, Stanley, additional, Cardenas, Maria C., additional, Knackstedt, Elizabeth Doby, additional, Goyal, Alka, additional, Jensen, M. Kyle, additional, Kaplan, Jess L., additional, Kellermayer, Richard, additional, Kociolek, Larry K., additional, Michail, Sonia, additional, Oliva-Hemker, Maria, additional, Reed, Anna W., additional, Weatherly, Madison, additional, Kahn, Stacy A., additional, and Nicholson, Maribeth R., additional

Published
2023
Full Text
View/download PDF

26. Clostridioides difficile Infection in Hospitalized Pediatric Patients: Comparisons of Epidemiology, Testing, and Treatment from 2013 to 2019

Author

Edwards, Price T., primary, Thurm, Cary W., additional, Hall, Matthew, additional, Busing, Jordan D., additional, Kahn, Stacy A., additional, Kellermayer, Richard, additional, Kociolek, Larry K., additional, Oliva-Hemker, Maria M., additional, Sammons, Julia S., additional, Weatherly, Madison, additional, Edwards, Kathryn M., additional, and Nicholson, Maribeth R., additional

Published
2023
Full Text
View/download PDF

29. Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection

Author

Zackular, Joseph P, Moore, Jessica L, Jordan, Ashley T, Juttukonda, Lillian J, Noto, Michael J, Nicholson, Maribeth R, Crews, Jonathan D, Semler, Matthew W, Zhang, Yaofang, Ware, Lorraine B, Washington, M Kay, Chazin, Walter J, Caprioli, Richard M, and Skaar, Eric P

Subjects
Zinc (Nutrient) -- Health aspects, Microbiota (Symbiotic organisms) -- Health aspects, Clostridium infections -- Risk factors -- Development and progression, Biological sciences, Health
Abstract

Author(s): Joseph P Zackular [1]; Jessica L Moore [2, 3]; Ashley T Jordan [1]; Lillian J Juttukonda [1]; Michael J Noto [1, 4]; Maribeth R Nicholson [5]; Jonathan D Crews [...]

Published
2016
Full Text
View/download PDF

30. Clostridioides difficileferrosome organelles combat nutritional immunity

Author

Pi, Hualiang, Sun, Rong, McBride, James R., Kruse, Angela R. S., Gibson-Corley, Katherine N., Krystofiak, Evan S., Nicholson, Maribeth R., Spraggins, Jeffrey M., Zhou, Qiangjun, and Skaar, Eric P.

Abstract

Iron is indispensable for almost all forms of life but toxic at elevated levels1–4. To survive within their hosts, bacterial pathogens have evolved iron uptake, storage and detoxification strategies to maintain iron homeostasis1,5,6. Recent studies showed that three Gram-negative environmental anaerobes produce iron-containing ferrosome granules7,8. However, it remains unclear whether ferrosomes are generated exclusively by Gram-negative bacteria. The Gram-positive bacterium Clostridioides difficileis the leading cause of nosocomial and antibiotic-associated infections in the USA9. Here we report that C. difficileundergoes an intracellular iron biomineralization process and stores iron in membrane-bound ferrosome organelles containing non-crystalline iron phosphate biominerals. We found that a membrane protein (FezA) and a P1B6-ATPase transporter (FezB), repressed by both iron and the ferric uptake regulator Fur, are required for ferrosome formation and play an important role in iron homeostasis during transition from iron deficiency to excess. Additionally, ferrosomes are often localized adjacent to cellular membranes as shown by cryo-electron tomography. Furthermore, using two mouse models of C. difficileinfection, we demonstrated that the ferrosome system is activated in the inflamed gut to combat calprotectin-mediated iron sequestration and is important for bacterial colonization and survival during C. difficileinfection.

Published
2023
Full Text
View/download PDF

32. Additional file 2 of Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes

Author

Bernard, Rachel, Hammami, Muhammad B., Arnold, Forest W., Mcgrath, Brian, Patel, Alieysa, Wuerth, Brandon, Nicholson, Maribeth R., Rao, Krishna, and Micic, Dejan

Abstract

Additional file 2: Table S1. ANOVA table for full model including toxin status, inpatient status and age for hemoglobin. Accompanying graph shows hemoglobin values across toxin status for both inpatients and outpatients. Table S2. ANOVA table for full model including toxin status, inpatient status and age for albumin. Accompanying graph shows serum albumin values across toxin status for both inpatients and outpatients.

Published
2022
Full Text
View/download PDF

33. Additional file 1 of Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes

Author

Bernard, Rachel, Hammami, Muhammad B., Arnold, Forest W., Mcgrath, Brian, Patel, Alieysa, Wuerth, Brandon, Nicholson, Maribeth R., Rao, Krishna, and Micic, Dejan

Abstract

Additional file 1: Table S1. Two-step assays utilized during the retrospective study from participating centers. Table S2. Breakdown of CDI testing from IBD patients from participating centers.

Published
2022
Full Text
View/download PDF

34. Fecal Microbiota Transplantation Across the Lifespan: Balancing Efficacy, Safety, and Innovation.

Author

Gulat, Ajay S., Nicholson, Maribeth R., Khoruts, Alexander, and Kahn, Stacy A.

Subjects
*FECAL microbiota transplantation, *CLOSTRIDIOIDES difficile
Abstract

Fecal microbiota transplantation (FMT) is a rapidly growing therapy aimed at reconstituting the dysbiotic microbiota of a patient with the beneficial stool microbiota of a healthy individual. The efficacy rates of FMT are very robust for recurrent Clostridioides difficile infection in both children and adults. Although complications of FMT have been reported, it is generally believed to be a safe procedure. Novel indications for FMT are being studied, with the hope that ultimately it may be useful for a variety of disorders. As this field continues to grow, however, it is necessary to consider efficacy, safety, and innovation across the lifespan. There are unique concerns regarding FMT as it pertains to children, adults, and the elderly. In this review, we seek to update clinicians, researchers, and regulators on how these factors must be balanced across the lifespan as we move forward with this innovative therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.

Author

Nicholson, Maribeth R, Alexander, Erin, Ballal, Sonia, Davidovics, Zev, Docktor, Michael, Dole, Michael, Gisser, Jonathan M, Goyal, Alka, Hourigan, Suchitra K, Jensen, M Kyle, Kaplan, Jess L, Kellermayer, Richard, Kelsen, Judith R, Kennedy, Melissa A, Khanna, Sahil, Knackstedt, Elizabeth D, Lentine, Jennifer, Lewis, Jeffery D, Michail, Sonia, and Mitchell, Paul D

Abstract

Background Children with inflammatory bowel disease [IBD] are disproportionally affected by recurrent Clostridioides difficile infection [rCDI]. Although faecal microbiota transplantation [FMT] has been used with good efficacy in adults with IBD, little is known about outcomes associated with FMT in paediatric IBD. Methods We performed a retrospective review of FMT at 20 paediatric centres in the USA from March 2012 to March 2020. Children with and without IBD were compared with determined differences in the efficacy of FMT for rCDI. In addition, children with IBD with and without a successful outcome were compared with determined predictors of success. Safety data and IBD-specific outcomes were obtained. Results A total of 396 paediatric patients, including 148 with IBD, were included. Children with IBD were no less likely to have a successful first FMT then the non-IBD affected cohort [76% vs 81%, p = 0.17]. Among children with IBD, patients were more likely to have a successful FMT if they received FMT with fresh stool [ p = 0.03], were without diarrhoea prior to FMT [ p = 0.03], or had a shorter time from rCDI diagnosis until FMT [ p = 0.04]. Children with a failed FMT were more likely to have clinically active IBD post-FMT [ p = 0.002] and 19 [13%] patients had an IBD-related hospitalisation in the 3-month follow-up. Conclusions Based on the findings from this large US multicentre cohort, the efficacy of FMT for the treatment of rCDI did not differ in children with IBD. Failed FMT among children with IBD was possibly related to the presence of clinically active IBD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition

Author

FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition, Davidovics, Zev H, Michail, Sonia, Nicholson, Maribeth R, Kociolek, Larry K, Pai, Nikhil, Hansen, Richard, Schwerd, Tobias, Maspons, Aldo, Shamir, Raanan, Szajewska, Hania, Thapar, Nikhil, de Meij, Tim, Mosca, Alexis, Vandenplas, Yvan, Kahn, Stacy A, Kellermayer, Richard, Clinical sciences, Growth and Development, Pediatrics, Pediatric surgery, AGEM - Digestive immunity, and Amsterdam Reproduction & Development (AR&D)

Subjects
medicine.medical_specialty, Disease, Inflammatory bowel disease, Pediatrics, Article, 03 medical and health sciences, 0302 clinical medicine, 030225 pediatrics, Internal medicine, medicine, Humans, Microbiome, Child, Pediatric gastroenterology, Enterocolitis, Pseudomembranous, Societies, Medical, Enterocolitis, business.industry, Clostridioides difficile, Gastroenterology, Clostridium difficile, Hepatology, Fecal Microbiota Transplantation, medicine.disease, Ulcerative colitis, Europe, Pediatrics, Perinatology and Child Health, North America, Practice Guidelines as Topic, 030211 gastroenterology & hepatology, medicine.symptom, business
Abstract

Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.

Published
2019
Full Text
View/download PDF

49. Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficileInfection in Pediatric Patients

Author

Bernard, Rachel, Hourigan, Suchitra K, and Nicholson, Maribeth R

Abstract

Clostridioides difficileinfection (CDI) is the most common cause of antibiotic-associated diarrhea and has high rates of recurrent disease. As a disease associated with intestinal dysbiosis, gastrointestinal microbiome manipulation and fecal microbiota transplantation (FMT) have evolved as effective, although relatively unregulated therapeutics and not without safety concerns. FMT for the treatment of CDI has been well studied in adults with increasing data reported in children. In this review, we discuss the current body of literature on the use of FMT in children including effectiveness, safety, risk factors for a failed FMT, and the role of FMT in children with comorbidities. We also review emerging microbial therapeutics for the treatment of rCDI.The safety and effectiveness of FMT in adults are well studied with growing data in children. As such, we review the current literature investigating the role of FMT in children and discuss emerging microbial therapeutics for recurrent Clostridioides difficileinfection.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results